GO2 Foundation’s Presence at The World Conference on Lung Cancer, 2022

This summer, the World Conference on Lung Cancer convened in Vienna, Austria. GO2 shared our research with this community as both lead authors and collaborators on several projects to help advance the diagnosis, treatment, and survival of people with lung cancer.
Advances in Treatment for Early Stage Non-small Cell Lung Cancer

For many years, the treatment options given to patients diagnosed with early stage non-small cell lung cancer was limited to surgery with or without chemotherapy to improve outcomes. However, like with metastatic NSCLC, the treatment landscape for patients with early-stage NSCLC has shifted much more towards a precision medicine approach. In this article we will give an overview of the new direction in treatment options before surgery (neoadjuvant), after surgery (adjuvant). Other advances in surgery, recurrence and outcome prediction, as well as how screening may change in the coming future is discussed.
Every person’s cancer is different, which is why we cannot use a one-size-fits-all approach to treatment. Precision medicine uses a person’s unique genetic profile to guide treatment decisions—and was a theme at this year’s ESMO and World Lung conferences. We’re recapping the latest news and key takeaways on precision medicine for late stage lung cancer—including oncogene targeted therapies, new targets for immuno-oncology, and genetic-driven therapy.
THANK YOU TO OUR SPONSORS

Genentech
A Member of the Roche Group

REGENERON

sanofi
Contact Us

Email: info@go2foundation.org  |  HelpLine: 1-800-298-2436 (9-5 EDT)

Washington, DC
Phone: 202-463-2080

San Francisco Bay Area
Phone: 650-598-2857
About Us

Founded by patients and survivors, GO2 Foundation for Lung Cancer transforms survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.

DONATE TODAY!